Summary
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago.
Beam Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 62 | $1,514.19 | $1,678.34 | $164.15 | 10.84% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 8,420 | $288,970 | $231,381.6 | -$57,588.4 | -19.93% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 691 | $18,198.23 | $18,553.35 | $355.12 | 1.95% |
 Farallon Capital Farallon Capital Management LLC | 10.24M | $406.12M | $273.82M | -$132.3M | -32.58% |
| NA Nizar Araji National Bank Of Canada /FI/ | 315 | $8,765.31 | $8,656.2 | -$109.11 | -1.24% |
Beam Therapeutics Inc. (BEAM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Beam Therapeutics Inc. ever had a stock split?
Beam Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Evans CEO | NASDAQ (NGS) Exchange | 07373V105 CUSIP |
| US Country | 540 Employees | - Last Dividend | - Last Split | 6 Feb 2020 IPO Date |
Overview
Beam Therapeutics Inc. is a pioneering biotechnology company focused on advancing the field of genetic medicines to address the needs of patients with serious diseases. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam Therapeutics stands at the forefront of developing innovative therapies using precise genome editing technologies. The company’s commitment to this mission is evidenced by its active engagement in several strategic collaborations with leading pharmaceutical and biotechnology companies including Pfizer Inc., Apellis Pharmaceuticals, Verve Therapeutics, Inc., Sana Biotechnology, Inc., and Orbital Therapeutics. These partnerships are aimed at leveraging in vivo base editing for targeting rare genetic diseases affecting the liver, muscle, and central nervous system; identifying gene targets within the complement system; enhancing treatments for cardiovascular disease; exploring CRISPR Cas12b for cell therapy programs; and designing RNA for the prevention, diagnosis, or treatment of human diseases, respectively.
Products and Services
Beam Therapeutics Inc. is actively developing a diverse portfolio of precision genetic medicines, including:
- BEAM-101: This forefront candidate is being developed as a potential treatment for sickle cell disease or beta-thalassemia, aiming to address the genetic root causes of these serious hematologic conditions.
- BEAM-302: A liver-targeting lipid nanoparticle (LNP) formulation designed to tackle severe alpha-1 antitrypsin deficiency, a genetic disorder that can cause liver and lung disease.
- BEAM-201: An anti-CD7 CAR-T product candidate currently in Phase 1/2 clinical trials for refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma, showcasing Beam’s commitment to innovating in the field of oncology with targeted cellular therapies.
- BEAM-301: Another liver-targeting LNP formulation, this time for the treatment of glycogen storage disease 1a, a genetic disorder that prevents the body from properly storing and utilizing glucose, leading to a variety of health issues.
In addition to product development, Beam Therapeutics Inc. collaborates on research initiatives aimed at pioneering new treatment paradigms. These include:
- Research collaboration with Pfizer Inc.: Focused on advancing in vivo base editing programs for rare genetic diseases of the liver, muscle, and central nervous system.
- Apellis Pharmaceuticals partnership: To conduct preclinical research targeting specific genes within the complement system across various organs, including the eye, liver, and brain.
- Verve Therapeutics, Inc. collaboration: Aimed at developing treatments for cardiovascular diseases.
- Sana Biotechnology, Inc. agreement: For the research, development, and commercialization rights to CRISPR Cas12b in cell therapy programs.
- Orbital Therapeutics design: Focused on RNA design for the prevention, treatment, or diagnosis of human diseases, augmenting the capabilities and reach of genetic medicine.
